Back to top
Read MoreHide Full Article

ImmunoGen, Inc. (IMGN - Free Report) was a big mover last session, as the company saw its shares surge 11% on the day. This jump can be attributable to solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend for the company as the stock is now down about 10.7% in the past one-month time frame.

In the last 30 days, this company did not witness any estimate revisions and the Zacks Consensus Estimate has remained unchanged over the same period. However, the recent price action is encouraging, so make sure to keep a close watch on this firm in the near future.

ImmunoGen currently has a Zacks Rank #1(Strong Buy) while its Earnings ESP is 0.00%.

Other strong players in the healthcare industry include Myriad Genetics Inc. (MYGN - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Aastrom Biosciences, Inc. all carrying the same rank as ImmunoGen.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

IMMUNOGEN INC (IMGN - Free Report) : Free Stock Analysis Report

MYRIAD GENETICS INC (MYGN - Free Report) : Free Stock Analysis Report

AASTROM BIOSCIENCES INC : Free Stock Analysis Report

ANI PHARMACEUTICALS INC (ANIP - Free Report) : Free Stock Analysis Report

Zacks Investment Research

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

ImmunoGen, Inc. (IMGN) - free report >>

Myriad Genetics, Inc. (MYGN) - free report >>

ANI Pharmaceuticals, Inc. (ANIP) - free report >>

More from Zacks Tale of the Tape

You May Like